Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

被引:21
|
作者
Chalmers, James D. [1 ]
van Ingen, Jakko [2 ]
van der Laan, Roald [3 ]
Herrmann, Jean-Louis [4 ,5 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland
[2] Radboud Univ Nijmegen, Radboudumc Ctr Infect Dis, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[3] Insmed BV, Utrecht, Netherlands
[4] Univ Paris Saclay, UVSQ, Infect & Inflammat, INSERM, Montigny Le Bretonneux, France
[5] Grp Hosp Univ Paris Saclay, Hop Raymond Poincare, AP HP, Garches, France
来源
EUROPEAN RESPIRATORY REVIEW | 2021年 / 30卷 / 161期
关键词
PSEUDOMONAS-AERUGINOSA INFECTION; MECHANICALLY VENTILATED PATIENTS; TIME-KILL KINETICS; AVIUM COMPLEX; CYSTIC-FIBROSIS; CELL-WALL; AMIKACIN CONCENTRATIONS; ENCAPSULATED-AMIKACIN; RESISTANCE MECHANISMS; ABSCESSUS COMPLEX;
D O I
10.1183/16000617.0010-2021
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] FACTORS ASSOCIATED WITH NONTUBERCULOUS MYCOBACTERIAL PULMONARY INFECTIONS
    Reechaipichitkul, Wipa
    Jantharaksa, Sirot
    Chaimanee, Prajaub
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2019, 50 (02) : 335 - 346
  • [22] Diagnosis and management of nontuberculous mycobacterial lung infections
    Teng Moua
    Timothy R. Aksamit
    Current Respiratory Care Reports, 2014, 3 (4): : 161 - 169
  • [23] Diagnosis and management of nontuberculous mycobacterial lung infections
    Moua, Teng
    Aksamit, Timothy R.
    CURRENT PULMONOLOGY REPORTS, 2014, 3 (04) : 161 - 169
  • [24] Airway Deposition And Retention Of Liposomal Amikacin For Inhalation In Patients With Pulmonary Nontuberculous Mycobacterial Disease
    Olivier, K. N.
    Maas-Moreno, R.
    Whatley, M.
    Cheng, K.
    Lee, J. -H.
    Fiorentino, C.
    Shaffer, R.
    Macdonald, S.
    Gupta, R.
    Corcoran, T. E.
    Malinin, V. S.
    Eagle, G.
    Perkins, W.
    Paik, C.
    Chen, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [25] Management of nontuberculous mycobacterial pulmonary disease
    Adelman, Mark H.
    Addrizzo-Harris, Doreen J.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (03) : 212 - 219
  • [26] Pharmacotherapy for nontuberculous mycobacterial pulmonary disease
    Velagapudi, Manasa
    Sanley, Michael J.
    Ased, Sumaya
    Destache, Chris
    Malesker, Mark A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (06) : 437 - 445
  • [27] Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease
    Cowman, Steven A.
    James, Phillip
    Wilson, Robert
    Cookson, William O. C.
    Moffatt, Miriam F.
    Loebinger, Michael R.
    PLOS ONE, 2018, 13 (12):
  • [28] Characteristics of clinical features and drug sensitivity of Nontuberculous Mycobacterial Pulmonary Disease
    Khachetlov, Ruslan
    Tinkova, Valentina
    Gudieva, Ilona
    Lizinfeld, Irina
    Gracheva, Alexandra
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 152
  • [29] Treatment outcomes of nontuberculous mycobacterial pulmonary disease in lung transplant recipients
    Hirama, Takashi
    Singer, Lianne G.
    Brode, Sarah K.
    Marras, Theodore K.
    Husain, Shahid
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [30] The Importance of Nontuberculous Mycobacterial Lung Disease
    Iseman, Michael D.
    Marras, Theodore K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (10) : 999 - 1000